MOUNTAIN VIEW, Calif., Sept. 4, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.
-
Morgan Stanley Global Healthcare Unplugged Conference, Grand Hyatt New York Hotel, New York, NY
- Wednesday, September 11, 2013, at 9:10 a.m. Eastern Time -
Stifel Nicolaus Annual Healthcare Conference, Four Seasons Hotel, Boston, MA
- Thursday, September 12, 2013, at 8:35 a.m. Eastern Time
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Archived webcasts will remain available on the Company's website for fourteen (14) days following each presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. Vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, is now being solely developed by GSK and is currently in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as CCX872, a CCR2 inhibitor, and CCX507, an inhibitor of CCR9, both of which are in Phase I clinical testing. ChemoCentryx also has several programs in advanced preclinical development.
CCXI-G
Source: ChemoCentryx, Inc.